Sanofi is a French multinational pharmaceutical and healthcare company headquartered in Paris. The group develops, manufactures, and markets prescription medicines and vaccines, with a strategic focus on immunology, rare diseases, and vaccines following the divestiture of its consumer health operations. Its flagship product is Dupixent, an immunology biologic co-developed with Regeneron (REGN), used to treat conditions such as atopic dermatitis, asthma, and other inflammatory diseases. Sanofi's American Depositary Receipts trade on the NASDAQ under the ticker SNY. Investors follow the stock closely for Dupixent's growth trajectory, the progress of its pipeline and business development efforts, and its dividend, which has increased for 31 consecutive years. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, SNY shares have risen approximately 19%, moving from a closing price near $40.61 to roughly $48.39. The advance was driven primarily by the company's third-quarter earnings release in late October, after which the stock posted a sharp single-day gain of nearly 6%.
The trailing-quarter picture is more nuanced. Measured from mid-August, when the stock traded near $44.41, shares ended the period modestly higher at about $48.39—a gain of roughly 9%. However, that headline figure masks significant volatility: Sanofi declined through late September and early October, dipping toward the $39 level before the post-earnings rebound restored and extended its gains.
The dominant catalyst was Sanofi's third-quarter 2026 earnings report, released on October 30. Total sales rose 14.3% at constant exchange rates to €14.44 billion, while business earnings per share increased 19.6% at constant exchange rates to €3.55. Dupixent was the standout performer, with sales jumping 34.8% to €5.7 billion—the second consecutive quarter above €5 billion.
Sanofi also raised its full-year 2026 outlook, now targeting low-teens percentage sales growth and mid-teens percentage business EPS growth at constant exchange rates. Management's commentary supported the bullish tone: CFO François Roger indicated the company could pursue acquisitions above its typical $2 billion to $5 billion range, and the group announced an expanded alliance with Regeneron (REGN) providing access to four new immunology compounds. Analyst reactions were constructive, with Citi raising its price target to €93 from €78 while maintaining a Neutral rating. From what I see, the earnings momentum here looks solid on the surface.
The quarterly narrative was shaped by two opposing forces. Through September and early October, investor sentiment was weighed down by concerns about Sanofi's heavy reliance on Dupixent—which accounts for roughly two-fifths of group sales—as well as softer vaccine sales and a pipeline viewed as needing replenishment. These worries pushed shares toward multi-year lows.
The tone shifted decisively with the third-quarter results and the accompanying strategic updates. Under CEO Belén Garijo, who took the helm in April 2026, Sanofi accelerated its transformation agenda, discontinuing lower-priority development programs, divesting legacy medicines through a Cheplapharm partnership, and signaling a more active approach to business development and M&A. Together, these steps reframed the story from one of Dupixent dependency toward a broader plan for sustainable growth, fueling the late-quarter rebound. I’m watching this closely as the company executes on those changes.
Looking ahead, several factors are likely to shape Sanofi's trajectory. The company's next earnings report is estimated for late January 2027, and investors will scrutinize whether Dupixent's momentum and cost discipline persist. Longer term, the central theme remains the preparation for Dupixent's loss of exclusivity in the early 2030s, which management has made its top strategic priority.
Other items to monitor include the pace and execution of business development and M&A, the progress of the expanded Regeneron (REGN) collaboration, vaccine revenue phasing, and pipeline milestones such as regulatory approvals and trial readouts. Sanofi has also flagged that pricing is expected to return to a slightly negative contribution in 2027 and that portfolio divestments could reduce sales by around €1.3 billion. These dynamics, along with broader macroeconomic and healthcare-policy developments, will be central to investor sentiment in the quarters ahead.
In my own research process, I often review Tickeron's Trending AI Robots to see how automated strategies are performing across a range of tickers. The page curates top bots based on recent results, offering a focused way to compare approaches without sifting through hundreds of options. It serves as a practical complement when evaluating names like SNY alongside systematic signals.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
The 10-day moving average for SNY crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on SNY as a result. In 52 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for SNY just turned positive on October 15, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in 24 of 47 cases over the following month. The odds of a continued upward trend are 51%.
SNY moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +0.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 154 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
The Aroon Indicator entered an Uptrend today. In 160 of 284 cases where SNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
SNY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock slightly worse than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.629) is normal, around the industry mean (-1.421). P/E Ratio (28.596) is within average values for comparable stocks, (21.700). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.169) is considerably higher than the industry average of (0.038). P/S Ratio (1.829) is also within normal values, averaging (4.033).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a producer of pharmaceutical products
Industry PharmaceuticalsMajor